L5 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2005:300304 CAPLUS Full-text
DN 142:367688
TI Use of galanthamine and the derivatives thereof in the production of medicaments for the treatment of postoperative delirium
IN Bodenteich, Angelika; Frantsits, Werner J.; Pirich, Eberhard; Czollner, Laszlo
PA Sanochemia Pharmazeutika A.-G., Austria
SO PCT Int. Appl., 62 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005030332	A2	20050407	WO 2004-AT251	20040712
WO 2005030332	A3	20050602		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI AT 2003-1538 A 20030929
OS MARPAT 142:367688
AB The invention discloses the use of galanthamine and the cholinergically active derivs. thereof in the production of medicaments for preventive treatment of postoperative delirium and/or subsyndronal postoperative delirium. Galanthamine, the galanthamine derivative(4aS,6R,8aS)-6-hydroxy-3- methoxy-11-methyl-4a,5,9,10-tetrahydro-6H-benzofuro[3a,3,2-ef] [2]benzazepinium bromide, and analogous salts, hydrates or solvates are suited for use according to the invention.
IT **273749-95-4**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)(galanthamine and galanthamine derivs. for treatment of postoperative delirium)
RN 273749-95-4 CAPLUS
CN 3H,6H-5,10b-Ethanophenanthridine-3,10-diol, 7-bromo-1,2,4,4a-tetrahydro-9-methoxy- (9CI) (CA INDEX NAME)



L5 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2000:383937 CAPLUS Full-text
DN 133:26864
TI Use of galanthamine and galanthamine derivatives for the treatment of acute functional brain damage
IN Mucke, Martin Alois Hermann; Frohlich, Johannes; Jordis, Ulrich
PA Sanochemia Pharmazeutika A.-G., Austria
SO PCT Int. Appl., 46 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000032199	A1	20000608	WO 1998-AT291	19981201
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9914300	A1	20000619	AU 1999-14300	19981201
PRAI WO 1998-AT291	A	19981201		

AB The invention relates to the use of galanthamine and analogs or acidic addition salts thereof in the production of medicaments for treating states arising from cerebrovascular accidents or closed focal craniocerebral traumas or whiplash injuries.
IT **273749-95-4**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (galanthamine and derivs. for treatment of acute functional brain damage)
RN 273749-95-4 CAPLUS
CN 3H,6H-5,10b-Ethanophenanthridine-3,10-diol, 7-bromo-1,2,4,4a-tetrahydro-9-methoxy- (9CI) (CA INDEX NAME)



RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1986:618421 CAPLUS Full-text
DN 105:218421
TI Clastogenic effect of hippeastidine (HIPP) (1,2,3,4,4a,6-hexahydro-10-hydroxy-3,8,9-trimethoxy-5,10b-ethanophenanthridine)
AU Alarcon, M.; Cea, G.; Weigert, G.
CS Fac. Biol. Sci. Nat. Resour., Univ. Concepcion, Concepcion, Chile
SO Bulletin of Environmental Contamination and Toxicology (1986), 37(4), 508-12
CODEN: BECTA6; ISSN: 0007-4861
DT Journal
LA English
GI



I

AB In a screening of chilean plants for anticancer activity, a number of alkaloids were isolated from Hippeastrum ananuca (Amaryllidaceae). HIPP (I) [66276-51-5] is the 1 that has been shown to exhibit the major antineoplastic activity as tested in KB cells (a human transformed nasopharyngeal cell line) showing an ED50 = 0.270 μg/mL, the dosage required to inhibit by 50% the growth of a cell population.

IT **66276-51-5**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)(antineoplastic activity of, in KB cells)
RN 66276-51-5 CAPLUS
CN 1H,6H-5,10b-Ethanophenanthridin-10-ol, 2,3,4,4a-tetrahydro-3,8,9-trimethoxy-, [3R-(3α,4aβ,5α,10bα)]- (9CI) (CA INDEX NAME)



L5 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1982:527844 CAPLUS Full-text
DN 97:127844
TI Hippeastidine, C17H23O4N
AU Watson, William H.; Zabel, Volker; Silva, Mario; Pacheco, Patricia
CS Dep. Chem., Texas Christian Univ., Fort Worth, TX, 76129, USA
SO Crystal Structure Communications (1982), 11(1), 157-62
CODEN: CSCMCS; ISSN: 0302-1742
DT Journal
LA English
AB The crystal structure of hippeastidine (1,2,3,4,4a,6-hexahydro-10-hydroxy-3,8,9-trimethoxy-5,10b-ethanophenanthridine) was determined the ring conformations were described.
IT **81904-08-7**
RL: PRP (Properties)
(crystal structure of)
RN 81904-08-7 CAPLUS
CN 1H,6H-5,10b-Ethanophenanthridine-3,10-diol, 2,3,4,4a-tetrahydro-8,9-dimethoxy-, [3R-(3α,4aβ,5α,10bα)]- (9CI) (CA INDEX NAME)



L5 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1982:214311 CAPLUS Full-text
DN 96:214311
TI Chemical study of Chilean Amaryllidaceae. II. New alkaloids from Hippeastrum ananuca Phil
AU Pacheco, Patricia Del C.; Silva, Mario J.; Sammes, Peter G.; Watson, William H.
CS Fac. Cienc. Biol. Recursos Nat., Univ. Concepcion, Concepcion, Chile
SO Boletin de la Sociedad Chilena de Quimica (1982), 27(2), 289-90
CODEN: BOCQAX; ISSN: 0366-1644
DT Journal
LA Spanish
GI



I

AB I, m. 175°, and hemanthamine, m. 205°, were isolated from H. ananuca bulbs, and identified by UV, IR, and H+-NMR spectroscopy.
IT **81904-08-7**
RL: BIOL (Biological study)
(of Hippeastrum ananuca bulb)
RN 81904-08-7 CAPLUS
CN 1H,6H-5,10b-Ethanophenanthridine-3,10-diol, 2,3,4,4a-tetrahydro-8,9-dimethoxy-, [3R-(3α,4aβ,5α,10bα)]- (9CI) (CA INDEX NAME)



L5 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1978:503746 CAPLUS Full-text
DN 89:103746
TI Alkaloids of Chilean Amaryllidaceae. I. Hippeastidine and epi-homolycorine, two novel alkaloids
AU Pacheco, P.; Silva, M.; Steglich, W.; Watson, W. H.
CS Dep. Bot., Univ. Concepcion, Concepcion, Chile
SO Revista Latinoamericana de Quimica (1978), 9(1), 28-32 Published in: Rev. Latinoamer. Quim. 8(4)
CODEN: RLAQA8; ISSN: 0370-5943
DT Journal
LA English
GI



I



II

AB Lycorine, homolycorine, maritidine, hippeastidine (I), and epihomolycorine (II) were isolated from Hippeastrum ananuca bulbs. The total alkaloid extract was separated into 4 fractions, each of which showed antitumor activity in KB assay. The structures of I and II were assigned from spectral and x-ray diffraction data.

IT **66276-51-5**
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence) (of Hippeastrum ananuca)
RN 66276-51-5 CAPLUS
CN 1H,6H-5,10b-Ethanophenanthridin-10-ol, 2,3,4,4a-tetrahydro-3,8,9-trimethoxy-, [3R-(3α,4aβ,5α,10bα)]- (9CI) (CA INDEX NAME)



IT **66322-24-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 66322-24-5 CAPLUS
CN 1H,6H-5,10b-Ethanophenanthridin-10-ol, 2,3,4,4a-tetrahydro-3,8,9-trimethoxy-, [3R-(3α,4aβ,5α,10bα)]-, compd. with 2,4,6-trinitrophenol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 66276-51-5
CMF C18 H25 N O4



CM 2

CRN 88-89-1
CMF C6 H3 N3 O7



L5 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1978:136819 CAPLUS Full-text
DN 88:136819
TI 1,2,3,4,4a,6-Hexahydro-10-hydroxy-3,8,9-trimethoxy-5,10b-ethanophenanthridinium picrate
AU Watson, William H.; Taira, Zenei; Silva, Mario; Pacheco, Patricia
CS Dep. Chem., Texas Christian Univ., Fort Worth, TX, USA
SO Crystal Structure Communications (1977), 6(4), 797-801
CODEN: CSCMCS; ISSN: 0302-1742
DT Journal
LA English
AB The crystal structure of the title compound (hippeastidine picrate) was determined The conformation was discussed.
IT **66322-24-5**
RL: PRP (Properties)
(crystal structure of)
RN 66322-24-5 CAPLUS
CN 1H,6H-5,10b-Ethanophenanthridin-10-ol, 2,3,4,4a-tetrahydro-3,8,9-trimethoxy-, [3R-(3α,4aβ,5α,10bα)]-, compd. with 2,4,6-trinitrophenol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 66276-51-5
CMF C18 H25 N O4



CM 2

CRN 88-89-1
CMF C6 H3 N3 O7



IT **66276-51-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 66276-51-5 CAPLUS
CN 1H,6H-5,10b-Ethanophenanthridin-10-ol, 2,3,4,4a-tetrahydro-3,8,9-trimethoxy-, [3R-(3α,4aβ,5α,10bα)]- (9CI) (CA INDEX NAME)



L10 ANSWER 1 OF 1 MARPAT COPYRIGHT 2005 ACS on STN
AN 128:13368 MARPAT Full-text
TI New benzazepine derivatives, medicaments containing the same and their use to prepare medicaments
IN Czollner, Laszlo; Frohlich, Johannes; Jordis, Ulrich; Kuenburg, Bernhard
PA Sanochemia Ltd., Malta
SO PCT Int. Appl., 136 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9740049	A1	19971030	WO 1997-AT74	19970421
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AT 9600716	A	19971015	AT 1996-716	19960419
	AT 403803	B	19980525		
	AU 9724985	A1	19971112	AU 1997-24985	19970421
	EP 897387	A1	19990224	EP 1997-916263	19970421
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, FI				
	TW 224595	B1	20041201	TW 1997-86106195	19970509
	NO 9804852	A	19981116	NO 1998-4852	19981016
	US 2003092700	A1	20030515	US 1999-242339	19990211
	US 6638925	B2	20031028		
	US 2004067974	A1	20040408	US 2003-647283	20030826
PRAI	AT 1996-716	19960419			
	WO 1997-AT74	19970421			
	US 1999-242339	19990211			

GI



I



II

AB The synthesis of benzofuro[3a,3,2,ef][2]benzazepines (I) [R1,R2 = H, halo, CN, NC, OH, SH, SO3H, NH2, CF3, (un)substituted alkyl, (un)substituted alkoxy, (un)substituted aryl, (un)substituted aryloxy; R3 = OH, OMe; R4,R5 = H2, O, substituted O, (un)substituted alkyl, (un)substituted aryl, (un)substituted alkenyl, (un)substituted alkynyl, (un)substituted hydrazone, (un)substituted oxime; X = H2, O] and diazabicyclo[2.2.1]heptanes (II) [R8 = CH2Ph, 4-MeC6H4SO2, H, (un)substituted alkyl, Me3CO2C; R9 = (un)substituted Ph, CH2Ph, CHPh2, Me3CO2C] are described. Thus, I (R1 = Br, R2 = H, R3 = OMe, R4 = OH, R5 = H, R6 = H, X = H2) (III) was prepared by tartrate resolution of (±)-N-demethyl-8-bromogalanthamine. III in in vitro study showed an IC50 of >150 in υmol for the inhibition of acetylcholine esterase. Also disclosed are medicaments which contain compds. of formulas (I) and/or (II) and may be

successfully used for treating Alzheimer disease and related demential states, as well as the Langdon-Down syndrome.

MSTR 2



G1 = CH2CH2 (opt. substd.)
G5 = CH2
Patent location: claim 2
Note: additional ring formation specified

```
=> d l2; d his; log y
L2 HAS NO ANSWERS
L1                STR
```




```
Structure attributes must be viewed using STN Express query preparation.
L2                QUE  ABB=ON  PLU=ON  L1

      (FILE 'HOME' ENTERED AT 16:38:26 ON 24 AUG 2005)

      FILE 'REGISTRY' ENTERED AT 16:38:38 ON 24 AUG 2005
L1                STRUCTURE UPLOADED
L2                QUE L1
L3              1 S L2
L4              4 S L2 FUL

      FILE 'CAPLUS' ENTERED AT 16:39:17 ON 24 AUG 2005
L5              7 S L4

      FILE 'BEILSTEIN' ENTERED AT 16:39:55 ON 24 AUG 2005
L6              1 S L2 FUL
L7              0 S L6 NOT L5

      FILE 'MARPAT' ENTERED AT 16:40:26 ON 24 AUG 2005
L8              0 S L2
L9              1 S L2 FUL
L10             1 S L9 NOT L5


COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                             118.15     314.86

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)    SINCE FILE      TOTAL
                                                   ENTRY    SESSION
CA SUBSCRIBER PRICE                              -0.68      -5.79

STN INTERNATIONAL LOGOFF AT 16:41:12 ON 24 AUG 2005
```